Printer Friendly

APPOINTMENT OF TWO VICE PRESIDENTS COMPLETES CYGNUS SENIOR MANAGEMENT TEAM

 REDWOOD CITY, Calif., May 20 /PRNewswire/ -- Cygnus Therapeutic Systems (NASDAQ: CYGN), a company focused on transdermal drug delivery, today announced the appointments of Roger P. Francis and James F. Grady Jr. Ph.D., as vice presidents of Business Development and Human Resources, respectively. These appointments round out the senior management team assembled to lead the company.
 Cygnus has one product, Nicotrol(R), "the waking hours nicotine patch," on the market through Warner-Lambert's Parke-Davis Division. Two other products, a seven-day estradiol transdermal system for menopausal symptoms and a 24-hour fentanyl transdermal patch for postoperative pain, are nearing the end of Phase III clinical trials. A portfolio of over a dozen other products is in various stages of development from research to early clinical testing.
 "We have put together a fine team of executives with experience in pharmaceutical and biomedical firms," said Gary Cleary, chairman and founder of Cygnus. "This includes several long-term managers as well as the people we have brought on board in the last 18 months."
 Cygnus now has a full line-up of professional managers to put into effect the company strategy of becoming more involved in all stages of product development and commercialization. The company will continue to work with pharmaceutical or consumer product partners for many of its products, but also intends to become more active in clinical trials and selective product marketing.
 Francis, who joined Cygnus April 15 as vice president, Business Development, was for the past four years director, Licensing & Business Planning for ICI Americas Inc. Pharmaceutical Group. His history with ICI, a British-owned company, goes back to 1972 and includes extensive experience analyzing and negotiating pharmaceutical licensing agreements worldwide in transactions up to half a billion dollars in size, many with large pharmaceutical firms, including Merck, Miles Labs, Abbott and Wyeth-Ayerst.
 Francis' background combines deal-making and strategic market planning for product portfolio purposes. He has experience with acquisition, licensing and divestiture deals, as well as copromotion arrangements. Of particular value in the current environment of health care cost containment is his experience in health economics analysis, the determination of costs and benefits of a particular drug. "I've been responsible for economic analysis for all types of deals," he said. "At the same time, I've done strategic business planning for products. I look forward to applying my global outlook to managing and developing Cygnus' partnerships for our growing portfolio of products."
 Francis' pharmaceuticals background includes clinical experience with animal health trials, manufacturing, marketing and sales, project coordination and strategic planning. He holds a B.S. in industrial management from the University of Maryland and an M.B.A. from Widener College in marketing and economics.
 Grady joined Cygnus on May 18 as vice president, Human Resources. Grady has 15 years of human resource management experience in biomedical companies. Before joining Cygnus, he lead the Human Resources function at Beckman Instruments in Palo Alto. Earlier, he was director of Compensation and Organizational Development for the pharmaceutical R&D business unit of SmithKline Beckman (now SmithKline Beecham). Prior to that, he was director of Personnel and Human Resources Development at the National Board of Medical Examiners. Grady's experience incorporates many aspects of human resources management, from organizational design and development through recruitment and selection to team productivity, job evaluation and succession planning.
 He brings to Cygnus a strategic approach to organizational planning and development, useful in managing future growth at Cygnus. His experience leading, establishing and supporting continuous improvement and total quality efforts is particularly applicable to Cygnus manufacturing operations.
 Alan F. Russell, Ph.D., joined Cygnus in May 1992 as vice president, Scientific Affairs, responsible for regulatory affairs, medical/clinical affairs, project management, quality control and quality assurance. Russell was vice president for Scientific Affairs at Chiron Corp. for five years and held similar positions for four years at Beecham and for over 10 years at Syntex. He received a Ph.D. in organic chemistry from the University of New South Wales, and an M.B.A. and J.D. from the University of Santa Clara. Russell is managing new product development to ensure expeditious regulatory review and will be leading the company into greater involvement with clinical testing and FDA approvals. As Cygnus brings its family of eight female hormone replacement patches to market over the next few years, it will make increasing use of Dr. Russell's extensive background in bringing multiple products to market.
 Bruce K. Bennett, vice president, Operations, joined Cygnus in May of 1992 as vice president, Operations, to manage the manufacture of Nicotrol and future products developed by Cygnus. He brings to Cygnus over 17 years of experience as a manufacturing executive, 14 in health care companies. These include the Pacemaker Division of Intermedics, American Hospital Supply's McGaw Laboratories and the Kendall Co.'s Respiratory Care Division. Most recently, he was vice president of manufacturing at Progress Lighting, a division of Hansen plc, from 1989 to 1992. Bennett holds a B.S. in industrial technology from the University of California, Long Beach, and an MBA from Pepperdine University.
 Although Steven B. Engle became vice president, Marketing at Cygnus in May 1992, his association with the company started in August 1991, when he was a management consultant and acting vice president for Manufacturing, helping Cygnus with FDA approval and commercialization of Nicotrol(R). Engle has over 13 years of experience in sales and marketing as both an executive and an advisor for pharmaceutical, biotechnology and electronic companies. A co-founder of Strategic Decisions Group, Engle's clients have included Ciba-Geigy (Alza), DuPont Merck Pharmaceuticals, Hoffman-LaRoche and Proctor & Gamble. He was vice president of Marketing for Micro Power Systems, a subsidiary of Seiko Corp. from 1984-87.
 An expert in product planning and portfolio management, Engle was an Eli Lilly & Co. Clinical Scholar and Visiting Professor in 1991. Engle holds both a B.S.E.E. and an M.S.E.E. with a biomedical engineering major from the University of Texas at Austin. At Cygnus, Engle is responsible for product management, market research and company-wide strategic planning. His experience working with international companies has given him a global and strategic marketing perspective that is particularly valuable as Cygnus brings more products to market.
 Gregory B. Lawless, Ph.D., became president and chief executive officer and director in January 1992. From 1989-92, Lawless was president and chief operating officer of Chiron Corp. Prior to his association with Chiron, he held various positions with the DuPont Co. from 1969-1989, including serving as chief operating officer of its pharmaceutical subsidiary and as director of DuPont's Specialty Diagnostics Division. His Ph.D. in Pharmaceutical Chemistry is from Temple University. Lawless' knowledge of the pharmaceutical industry and its products, combined with his strategic marketing focus, will help Cygnus evolve from a technology-driven R&D company to a market-driven drug delivery developer, manufacturer and marketer.
 Shirley L. Clayton joined the company in 1990 as vice president, Finance and chief financial officer. She was chief financial officer at Protein Design Labs Inc. from 1988-90, and she served as vice president and treasurer of Genentech Inc. from 1981-88. Prior to that, she was head of a corporate banking group at the Bank of America. She holds a BA in chemistry from Smith College and an M.B.A. from the Stanford Graduate School of Business. Clayton combines experience in managing the financial control and accounting function with practice in public and private financing for biotech companies.
 Thomas S. Spencer, Ph.D., joined Cygnus in 1988 as director of Research & Development, and was appointed vice president, Research & Development in March of 1992. Before his tenure with Cygnus, Spencer had 16 years experience in skin research, including eight years at S.C. Johnson and Son Inc., where he was manager of the Dermal Research Department. He combines experience in all phases of skin research, from skin permeability to cellular biology and skin hydration. His Ph.D. in physical chemistry is from Colorado State University and he was an assistant clinical professor at the Department of Dermatology, Medical College of Wisconsin. Spencer's guidance of the R&D efforts of the company have borne fruit in the extensive portfolio of products moving rapidly from research to clinical testing.
 Gary W. Cleary, Ph.D., founded Cygnus in 1985. He served as president and chief executive officer from founding until 1986, and is now chairman of the board of directors and chief technical officer. Before founding Cygnus, Cleary was involved in the development of three of the first five commercially available transdermal drug delivery products: scopolamine, clonidine and nitroglycerin. At Key Pharmaceuticals he developed drug delivery products including the nitroglycerin patch. At Alza Corp. Cleary was project leader for their scopolamine and clonidine patches. This experience led him to start Cygnus in order to integrate all the science and technology needed to develop and manufacture the new generation of transdermal systems.
 Earlier in his professional career, Cleary was an investigator with the U.S. F.D.A. and held research and management positions at Cutter Labs and Genentech. Cleary holds and M.B.A. from the University of Miami, a Ph.D. in pharmaceutical sciences from Rutgers University and a PharmD. in Pharmacy from the University of California, San Francisco. In addition to creating the Cygnus culture of technical and scientific excellence, Cleary had the foresight to find and appoint senior managers with strong business and marketing backgrounds as well as biopharmaceutical experience. This balanced approach to management will facilitate Cygnus' continuing transformation into a fully integrated medical technology company.
 -0- 5/20/93
 /CONTACT: Shirley Clayton of Cygnus, 415-369-4300/
 (CYGN)


CO: Cygnus Therapeutic Systems ST: California IN: MTC SU: PER

TM-GT -- SJ001 -- 1013 05/20/93 18:33 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 20, 1993
Words:1611
Previous Article:EXPEDITORS INTERNATIONAL ANNOUNCES CASH DIVIDEND PROGRAM
Next Article:EASTEC '93 OPENS TUESDAY: SOLD-OUT MANUFACTURING EXPO REFLECTS CONTINUING INTEREST IN EAST COAST ECONOMY
Topics:


Related Articles
CYGNUS ANNOUNCES NEW SCIENTIFIC AFFAIRS VP FORMERLY WITH CHIRON, BEECHAM, SYNTEX IN SENIOR REGULATORY POSITIONS
CYGNUS BOARD OF DIRECTORS NAMES ANTHONY CHAN CFO
LA JOLLA APPOINTS CHIEF OPERATING OFFICER
DR. NEIL ACKERMAN JOINS CYGNUS AS VICE PRESIDENT OF RESEARCH AND DEVELOPMENT
CYGNUS NAMES JOHN HODGMAN AS CHIEF FINANCIAL OFFICER
CYGNUS PROMOTES TWO OFFICERS; ROGER FRANCIS AND ALAN RUSSELL NAMED SENIOR VICE PRESIDENTS
Alan F. Russell, Ph.D. Named President and CEO of AvMax, Inc.
Cygnus Business Media Announces Executive Appointment; Strengthens Infrastructure and Refines Organization.
Cygnus Business Media Announces Appointment of Jeff Price to Oversee Cygnus Expositions Division.
Cygnus Business Media Announces Appointment of Carl Fazio As Chief Financial Officer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters